NR3C1 and cancer: We demonstrate that GR activation induces cancer cell dormancy, accompanied by a diminished response to a large array of anticancer drugs, activation of growth factor survival signalling (IGF-1R) and acquisition of vulnerability to IGF-1R inhibitors in cell lines and xenograft models.